This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
Biotech ETF (BBH) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
Gilead's (GILD) Coronavirus Drug Shows Promise, Shares Gain
by Zacks Equity Research
Treatment with Gilead's (GILD) experimental antiviral, remdesivir, shows rapid recoveries in fever and respiratory symptoms in COVID-19 patients in a Chicago hospital.
Powerful Proof Anyone Can Invest for an Early Retirement - April 17, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
The Zacks Analyst Blog Highlights: Microsoft, Walmart, Amgen, salesforce.com and Mondelez International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Walmart, Amgen, salesforce.com and Mondelez International
The Zacks Analyst Blog Highlights: Cardinal Health, Enphase Energy, Netflix, Amgen and Costco Wholesale
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cardinal Health, Enphase Energy, Netflix, Amgen and Costco Wholesale
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
6 Recession-Proof Picks Amid Coronavirus-Led "The Great Lockdown"
by Radhika Pujara
Coronavirus outbreak-induced global lockdowns are making recession inevitable. Here are six recession-resistant stocks including Netflix (NFLX) to beat COVID-19 induced recession woes.
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
Top Stock Reports for Microsoft, Walmart & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Walmart (WMT) and Amgen (AMGN).
ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure
by Sweta Jaiswal, FRM
Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.
Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.
Want To Retire Early? Learn the Intelligent Investing Secret - April 09, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
by Sweta Jaiswal, FRM
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.
3 Top Dividend Stocks to Maximize Your Retirement Income - April 06, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
by Kinjel Shah
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection
by Zacks Equity Research
Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.
Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN)
by Benjamin Rains
Regeneron Pharmaceuticals, Inc. (REGN) shares have surged 30% in 2020 as investors clamor for stocks that appear immune to the coronavirus economic downturn...
The Extreme Risks of Trading Your Own Retirement Assets - April 02, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Powerful Proof Anyone Can Invest for an Early Retirement - April 01, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.